Briacell Therap (NASDAQ:BCTX) Announces Quarterly Earnings Results

Posted by Brian Himes on Jun 9th, 2026

Briacell Therap (NASDAQ:BCTX – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.99) earnings per share for the quarter, Zacks reports.

Briacell Therap Price Performance

Shares of BCTX stock traded down $0.02 during trading hours on Tuesday, hitting $3.07. The company had a trading volume of 301,364 shares, compared to its average volume of 373,176. The company’s fifty day moving average is $3.91 and its 200 day moving average is $5.44. Briacell Therap has a fifty-two week low of $2.93 and a fifty-two week high of $36.00. The stock has a market capitalization of $26.71 million, a PE ratio of -0.13 and a beta of 1.21.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on BCTX

Briacell Therap Company Profile

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.